At a glance
ClinicalIndex Comparison RecordN/ACompleted
Drug / intervention
Abacavir sulfate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Dec 21, 2001·Updated Jul 29, 2013
In Brief
A clinical study evaluating Abacavir sulfate, Atazanavir/Ritonavir, and 2 other interventions for HIV Infections and 2 related conditions. Completed, across 25 sites.
Detailed Summary
The goals of this study are to find out if fat wasting and weight loss in the arms and legs of HIV patients taking highly active antiretroviral therapy (HAART) are caused by nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and if wasting can be reversed if the NRTI is stopped and replaced with other anti-HIV drugs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Lipodystrophy, Wasting Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2001
Enrollment StartMar 2002
Study CompletionMar 2005
TodayJul 2026
First PostedDec 21, 2001
Enrollment StartMar 1, 2002
Study CompletionMar 1, 2005
TodayJul 2, 2026
Posted 24.5 years ago
Interventions
Abacavir sulfatedrug
Atazanavir/Ritonavirdrug
Lopinavir/Ritonavirdrug
Nevirapinedrug